Screener
Emergent Biosolutions EBS Commercial Product sales — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001367644-26-000082
| Line item | Three Months Ended June 30, 2026 / USG | Three Months Ended June 30, 2026 / Non-USG | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / USG | Three Months Ended June 30, 2025 / Non-USG | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|
| Commercial Product sales | $1.0 | $51.4 | $52.4 | $1.2 | $66.3 | $67.5 |
| MCM Product sales | 148.6 | 19.4 | 168.0 | 46.0 | 12.4 | 58.4 |
| All other revenues (1) | 7.5 | 6.4 | 13.9 | 10.6 | 4.4 | 15.0 |
| Total revenues | $157.1 | $77.2 | $234.3 | $57.8 | $83.1 | $140.9 |
| (1) “All other revenues” includes Services and Contracts and grants revenue. |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Emergent Biosolutions's commercial product sales — total revenues?
- Emergent Biosolutions (EBS) reported commercial product sales — total revenues of $52.4M in Q2 2026.
- How has Emergent Biosolutions's commercial product sales — total revenues changed year-over-year?
- Emergent Biosolutions's commercial product sales — total revenues decreased by 22.4% year-over-year, from $67.5M to $52.4M.
- What is the long-term trend for Emergent Biosolutions's commercial product sales — total revenues?
- Over 4 years (2021 to 2025), Emergent Biosolutions's commercial product sales — total revenues has grown at a -15.2% compound annual growth rate (CAGR), from $438M to $226.1M.
- What does commercial product sales — total revenues mean?
- This metric represents the total gross revenue generated from the sale of commercial products within a specific business segment. It reflects the market demand and pricing power for the company's non-government or retail-focused product portfolio. Monitoring this figure helps investors assess the segment's top-line growth trajectory and its contribution to the company's overall commercial success.
Ask your AI about Emergent Biosolutions's commercial product sales — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude